Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

Autoimmune diseases, which are estimated to affect more than 15 million people in the U.S., occur when the body responds to immune-system false alarms, and infection-fighting first responders are sent ...

Imagine a world where bacteria, typically feared for causing disease, are turned into powerful weapons against cancer. That’s ...

Recent human trials of a new one-year-long immune-based treatment for post-polio syndrome, which can strike polio survivors ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced ...

A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...

A new type of antibody which stimulates the immune system to target cancer cells slows tumour growth, according to new research.